1. Scrip
  2. >>Business

Finance Watch: CF Foundation Commits $110m In Partnership With Flagship’s Pioneering Medicines

Service Providers lead $1.75bn In VC Mega-Rounds

 
• By Mandy Jackson

Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.

Finance Watch Private Company

The biotechnology company creator and funder Flagship Pioneering and the Cystic Fibrosis Foundation announced a strategic partnership on 3 November under which the CF Foundation has committed up to $110m to Pioneering Medicines, Flagship’s strategic initiative designed to extend the reach of the firm’s portfolio company technology platforms into new areas. The aim of the CF Foundation collaboration is to develop medicines for cystic fibrosis patients who do not benefit from available therapies.

Tessera Therapeutics, a Flagship-founded company that closed a $230m series B round in January, also announced that it will...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.